Article
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
Haemophilia : the official journal of the World Federation of Hemophilia - 1 Mar 1999
Thorland E C, Drost J B, Lusher J M, Warrier I, Shapiro A, Koerper M A, Dimichele D, Westman J, Key N S, Sommer S S
Abstract excerpt
Haemophilia B is an X-linked recessive coagulopathy due to mutations in the factor IX gene. Occasionally, patients receiving factor IX replacement therapy develop inhibiting antibodies to the factor IX protein, and it has been recently documented that a subset of these patients have had anaphylactic responses to factor IX replacement therapy in association with the development of inhibiting antibodies. To...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
